Tonix Pharmaceuticals Inc. (NASDAQ:TNXP) Stock Falls In a Week: Now What?

Tonix Pharmaceuticals Inc. (NASDAQ:TNXP) is down 5% in a week. The company has appointed Carolyn E. Taylor to its Board of Directors as of July 16, 2021. CEO Seth Lederman said they are delighted to have Ms. Taylor on board.

She has over 35 years of corporate law experience, including six years as general counsel in two start-up firms and 15 as a Covington & Burling LLP partner. He added that her extensive transactional experience would be helpful to the company as it grows. Taylor said she is looking forward to looking with other Board members and the Tonix management team in various strategic initiatives.

The company has also announced that it plans to develop TNX-102 SL as a possible Long COVID Syndrome treatment. Lederman said that the company would meet the FDA in Q3 2021 to discuss the design of the possible second phase pivotal study of TNX-102 SL in Long COVID. So in the coming weeks, TNXP is a stock worth watching.

Market Reaction:

On Tuesday, TNXP stock fell 2.20% at $0.96 with more than 7.71 million shares, compared to its average volume of 10.15 million shares. The stock has moved within a range of $0.9500 – 0.9900 after opening the trade at $0.97. Over the past 52-week, the stock has been trading within a range of $0.5100 – 2.1200.